Horimed Secures Tens of Millions in New Funding to Accelerate Development and Commercialization of Intravascular Interventional Imaging Products; HaoYue Capital Continues as Exclusive Financial Advisor

Nov 03, 2023 10:02 CST Updated 10:02

Horimed

OCT Imaging Equipment R&D and Manufacturer

Horimed Values

MissionEmpower with Capital, Achieve Excellence in Healthcare Enterprises

VisionTo become the most outstanding investment bank in China's healthcare industry

HaoYue Capital, founded in January 2014, is a leading investment bank in China that focuses on the healthcare industry. Headquartered in Shanghai, the company has regional offices in Beijing and Shenzhen. HaoYue Capital is committed to leveraging capital and research-driven insights to help outstanding enterprises in China's healthcare sector successfully access the capital markets and create added value for clients. The partnership team at HaoYue Capital comprises seasoned investment bankers with deep expertise in China’s healthcare industry. The firm closely tracks market dynamics and investment trends in healthcare, with research and transaction coverage spanning innovative pharmaceuticals, cutting-edge medical devices, IVD and life sciences, health services, and digital healthcare. As of 2022, HaoYue Capital has completed over 300 projects with a total transaction value exceeding tens of billions of US dollars, including more than 50 M&A and restructuring deals worth over 50 billion US dollars. In 2022 alone, HaoYue Capital executed over 50 private equity financings, M&A integrations, and complex spin-off transactions involving listed companies, with a total deal value reaching several billion US dollars, maintaining its leadership across various sub-sectors of the healthcare industry.

Recently,Horimed Technology Co., Ltd. (hereinafter referred to as "Horimed") announced the completion of a multi-million yuan financing round, exclusively invested by Beiyang Haitang Fund. This is the second financing completed by Horimed within three months after receiving tens of millions of yuan in investment from Jinhuitong Fund earlier this year, fully reflecting the high recognition from the capital market. Haoyue Capital has continuously served as the exclusive financial advisor. This round of financing will support R&D, production, and registration, with a key focus on accelerating the commercial promotion of already listed products.

Horimed Technology Co., Ltd. (Tianjin) was founded in 2016, focusing on the independent research, production, and sales of Intravascular Ultrasound (IVUS) equipment and catheters, Optical Coherence Tomography (OCT) equipment and catheters, dual-catheter systems with an all-in-one IVUS/OCT machine, Fractional Flow Reserve (FFR) platforms based on IVUS and OCT, single-source dual-modality OCT-NIRS technology integrating OCT and Near-Infrared Spectroscopy (NIRS), and intravascular laser plaque ablation technology. The company has mastered optical, ultrasound, and catheter platform technologies and continues to innovate globally based on core technologies. It is committed to providing an integrated pan-vascular solution based on imaging products for medical professionals and patients.

HorimedFounderMr. Liu ZhiyongExpressed,The precision diagnosis and treatment of vascular intervention in China has just started, and we still have a long way to go. We are very grateful for the consistent support from our old and new shareholders, and also thank our financing partner, Haoyue, for this round of funding.With strong capital and project execution capabilities, as well as deep and precise insights into the industry, Horimed Technology Co., Ltd. is poised to become a leader in intelligent endovascular diagnosis and treatment, driven by solid, innovative technologies and products under the support of capital.

Dr. Shi-Yong Zhao, Founder of HorimedRepresents,As a part of the precision diagnosis and treatment in vascular intervention, Horimed will not only focus on technology and products in the future but also concentrate on assisting clinical practice in conducting systematic training for precision diagnosis and treatment in vascular intervention. We hope to grow together with the majority of vascular intervention doctors, enabling more and more doctors to understand, master, and commit to promoting vascular intervention.Interventional precision diagnosis and treatment gradually align China with international standards in this field, ultimately benefiting more patients.

Mr. Wang Renda, Initiating Partner of Beiyang Begonia FundIt is reported that the development of intravascular imaging has greatly promoted the popularization of precision PCI procedures. Among these, IVUS and OCT can significantly improve the accuracy of PCI procedures, which is highly beneficial for patient prognosis and reduces the incidence of postoperative adverse events. This has become a consensus among industry experts. Currently, the penetration rate of IVUS and OCT in China lags significantly behind that in Europe and the United States, but the future trend towards accelerated adoption is clear. IVUS and OCT equipment and catheters represent a typical integration of interdisciplinary technologies involving sound, light, electricity, and imaging, with high barriers to entry and significant challenges in talent cultivation. Horimed boasts a top-tier team in China combining medical and engineering expertise, with years of R&D and industrialization experience, making it a leading company in the domestic IVUS and OCT market. The company's products have already been adopted by several Class A tertiary hospitals, and further promotion efforts will continue to benefit more patients. Haitang Fund remains committed to supporting innovation and entrepreneurship among Tianjin University alumni and will continue to contribute to the growth of Horimed as well as the advancement of precision vascular intervention.

HaoyueCapital ManagementPartnerMr. Yang ZhenjunTableWe are honored to assist Horimed in completing this round of financing, which is the second financing completed by Horimed within 3 months, fully reflecting the high recognition from the capital market. Comprehensive and precise diagnosis and treatment are the trend of medical development. Intravascular imaging is the most powerful technique for achieving accurate diagnosis in the field of vascular intervention and has been recommended by clinical guidelines and widely recognized in high-end medical markets globally. In recent years, intravascular imaging in China has achieved rapid growth driven by healthcare reform and trends such as the further penetration of interventional procedures, indicating significant growth potential in the future. All products of Horimed have full independent intellectual property rights, with core components developed entirely in-house. The company owns platform-level technology and has the capability for large-scale production of equipment and consumables as well as cost control. Heryue Capital continues to have a positive outlook on the company, growing together with the enterprise. We look forward to more high-quality products from the company reaching the market soon, benefiting a wide range of patients.

END

▽

About Horimed

Horimed Technology Co., Ltd., established in 2016, focuses on the independent research, production, and sales of IVUS equipment and catheters, OCT equipment and catheters, IVUS/OCT integrated dual-catheter systems, non-invasive FFR platforms based on IVUS and OCT, single-source dual-modality technology combining OCT and NIRS, and intravascular laser plaque ablation technology. The company has mastered optical, ultrasound, and catheter platform technologies and continues to innovate globally based on core technologies. It is committed to providing an integrated pan-vascular solution based on imaging products for medical professionals and patients.

About Beiyang Begonia Fund

Beiyang Haitang Fund was co-founded by renowned alumni entrepreneurs from Tianjin University. It aims to create a "Stanford + Silicon Valley" model for Tianjin University and promote the formation of an entrepreneurial ecosystem among its alumni. Its mission is to become the first partner for Tianjin University alumni on their entrepreneurial journey. Beiyang Haitang Fund focuses on using the fund to drive the construction of an innovation and entrepreneurship ecosystem, discovering, empowering, and investing in a group of scientific and technological achievements with industrialization and commercialization value, helping transform research results into market-demand-driven products. Since its establishment over three years ago, the fund has invested in more than 30 entrepreneurial projects primarily led by Tianjin University alumni, with investments and associated funding reaching nearly 2 billion RMB. The first phase of the Haitang Fund, sized at 100 million RMB, has been fully invested across 17 projects. The second phase of the Haitang Fund, serving as the Haitang Mother Fund, includes contributions from 14 listed companies and several well-known corporate groups, with a fund size of 540 million RMB, and has completed investments in more than 10 projects. The Haitang Tuobozi Fund is now officially operational, while the Tiangao Higher Education Sub-Fund is currently being established. Other sub-funds are progressing in an orderly manner. Upon completion of all sub-funds, the total management scale of the Beiyang Haitang Fund is expected to reach approximately 2 billion RMB. Based on building the "Nine Ones" entrepreneurial service framework for the Tianjin University alumni entrepreneurial ecosystem, it truly embodies the Tianjin University spirit of "alumni helping alumni, alumni leading alumni, and alumni investing in alumni."

Click the image to learn moreHaoyue Transaction